Literature DB >> 17225013

Predicting factors of interstitial lung disease in dermatomyositis and polymyositis.

Yi-Ju Chen1, Chun-Ying Wu, Jui-Lung Shen.   

Abstract

The aim of this study was to define the predicting factors and evaluate the prognosis of interstitial lung disease in dermatomyositis/polymyositis. For the period 1995-2005, we retrospectively reviewed the clinical information and laboratory data of 56 patients who were diagnosed as definite and probable dermatomyositis and polymyositis. Interstitial lung disease is common (41.9%) in these patients. Dyspnoea and cough were the two most common initial presentations. Anti-Jo1 antibody was more common in those with interstitial lung disease. Univariate and multivariate analyses identified primary idiopathic dermatomyositis subtype, cough and dyspnoea at onset to be the three independent clinical predicting factors of interstitial lung disease. High serum lactate dehydrogenase level (>400 U/l) was inversely associated with development of interstitial lung disease (OR 0.088, p=0.031). Serum lactate dehydrogenase level and presence of anti-Jo1 antibody can serve as laboratory indicators of lung complications. Patients with malignancy and older age at onset (more than 60 years) had poorer prognosis for dermatomyositis/polymyositis (p=0.047 and p=0.035, respectively). Interstitial lung disease did not affect the survival of dermatomyositis/polymyositis patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17225013     DOI: 10.2340/00015555-0177

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  7 in total

Review 1.  Cyclophosphamide treatment for idiopathic inflammatory myopathies and related interstitial lung disease: a systematic review.

Authors:  Yongpeng Ge; Qinglin Peng; Sigong Zhang; Hang Zhou; Xin Lu; Guochun Wang
Journal:  Clin Rheumatol       Date:  2014-11-01       Impact factor: 2.980

2.  Sex differential association of dermatomyositis with Sjögren syndrome.

Authors:  Chia-Chun Tseng; Shun-Jen Chang; Wen-Chan Tsai; Tsan-Teng Ou; Cheng-Chin Wu; Wan-Yu Sung; Ming-Chia Hsieh; Jeng-Hsien Yen
Journal:  CMAJ       Date:  2017-02-06       Impact factor: 8.262

3.  Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients.

Authors:  Rohit Aggarwal; Elaine Cassidy; Noreen Fertig; Diane Carol Koontz; Mary Lucas; Dana P Ascherman; Chester V Oddis
Journal:  Ann Rheum Dis       Date:  2013-02-19       Impact factor: 19.103

Review 4.  Patient-reported outcomes and adult patients' disease experience in the idiopathic inflammatory myopathies. report from the OMERACT 11 Myositis Special Interest Group.

Authors:  Helene Alexanderson; Maria Del Grande; Clifton O Bingham; Ana-Maria Orbai; Catherine Sarver; Katherine Clegg-Smith; Ingrid E Lundberg; Yeong Wook Song; Lisa Christopher-Stine
Journal:  J Rheumatol       Date:  2014-01-15       Impact factor: 4.666

5.  Interstitial lung disease in polymyositis and dermatomyositis.

Authors:  I-Jung Chen; Yeong-Jian Jan Wu; Cho-Wei Lin; Kang-Wei Fan; Shue-Fen Luo; Huei-Huang Ho; Lieh-Bang Liou; Wen-Pin Tsai; Ji-Yih Chen; Chung-Han Yang; Chang-Fu Kuo; Kuang-Hui Yu
Journal:  Clin Rheumatol       Date:  2009-02-27       Impact factor: 2.980

6.  Clinical characteristics and favorable long-term outcomes for patients with idiopathic inflammatory myopathies: a retrospective single center study in China.

Authors:  Xiao Ming Shu; Xin Lu; Yao Xie; Guo Chun Wang
Journal:  BMC Neurol       Date:  2011-11-09       Impact factor: 2.474

Review 7.  Factors Associated with Interstitial Lung Disease in Patients with Polymyositis and Dermatomyositis: A Systematic Review and Meta-Analysis.

Authors:  Li Zhang; Guoqin Wu; Di Gao; Guijian Liu; Lin Pan; Liyan Ni; Zheng Li; Qiang Wang
Journal:  PLoS One       Date:  2016-05-12       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.